Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.97
Handel nachbörslich:
4.99
4.99
+
Schlusskurs vom Vortag:
$4.97
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$48.77M
Einnahmen:
$21.73M
Nettoeinkommen (Verlust:
$-91.17M
KGV:
0.00
EPS:
-0.74
Netto-Cashflow:
$-286.43M
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$15.40
Bluebird Bio Inc Stock (BLUE) Company Profile
Firmenname
Bluebird Bio Inc
Sektor
Branche
Telefon
339-499-9300
Adresse
455 GRAND UNION BOULEVARD, SOMERVILLE, MA
Vergleichen Sie BLUE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BLUE
Bluebird Bio Inc
|
0.00 | 48.77M | 21.73M | -91.17M | -286.43M | -0.74 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Bluebird Bio Inc Stock (BLUE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-24 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-11-15 | Herabstufung | BofA Securities | Buy → Neutral |
| 2024-11-15 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-08-15 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-12-11 | Herabstufung | HSBC Securities | Hold → Reduce |
| 2023-12-08 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-10-17 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-07-19 | Hochstufung | BofA Securities | Neutral → Buy |
| 2023-06-01 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2023-04-28 | Eingeleitet | JP Morgan | Overweight |
| 2023-03-07 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2022-08-02 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2022-04-06 | Herabstufung | Cowen | Outperform → Market Perform |
| 2022-03-07 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-11-08 | Bestätigt | Barclays | Equal Weight |
| 2021-11-08 | Bestätigt | Canaccord Genuity | Hold |
| 2021-11-08 | Herabstufung | Goldman | Neutral → Sell |
| 2021-11-08 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-08 | Bestätigt | RBC Capital Mkts | Sector Perform |
| 2021-11-08 | Bestätigt | Wedbush | Neutral |
| 2021-11-08 | Bestätigt | Wells Fargo | Equal Weight |
| 2021-08-10 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-08-10 | Herabstufung | Goldman | Buy → Neutral |
| 2021-08-10 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2021-08-10 | Fortgesetzt | William Blair | Mkt Perform |
| 2021-08-09 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-07-01 | Herabstufung | Berenberg | Buy → Hold |
| 2021-03-10 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-02-17 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-02-16 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-02-16 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-12-09 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-11 | Eingeleitet | Berenberg | Buy |
| 2020-11-05 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2020-11-05 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2020-11-02 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2020-10-20 | Eingeleitet | Mizuho | Buy |
| 2020-05-13 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2020-03-27 | Hochstufung | Stifel | Hold → Buy |
| 2020-02-19 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-02-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2020-02-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-13 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-11-26 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2019-11-19 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-11-04 | Hochstufung | Wedbush | Neutral → Outperform |
| 2019-10-01 | Eingeleitet | Stifel | Hold |
| 2019-08-12 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2019-06-18 | Hochstufung | Maxim Group | Hold → Buy |
Alle ansehen
Bluebird Bio Inc Aktie (BLUE) Neueste Nachrichten
Car T Cell Therapy For Multiple Myeloma Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Bluebird bio, Cellectis SA, Caribou Biosciences, Luminary Therapeutics - Barchart.com
Shareholders That Lost Money on bluebird bio, Inc.(BLUE) Should Contact Levi & Korsinsky About Pending Class ActionBLUE - ACCESS Newswire
Unexpected Shifts in the Gene Transfer Technologies Market - openPR.com
Analyzing drawdowns of bluebird bio Inc. with statistical toolsWatchlist Summary for Active Day Traders - Newser
When is the best time to exit bluebird bio Inc.Weekly Price Target Forecast and Alerts - Newser
How moving averages guide bluebird bio Inc. tradingIntelligent Trade Forecast With AI Analytics - Newser
Historical volatility pattern of bluebird bio Inc. visualizedSafe Entry Screening with Data Backed Analysis - Newser
Risk vs reward if holding onto bluebird bio Inc.Free Daily Volume Spike Trading Signals - Newser
BLUEBIRD BIO Earnings Preview: Recent $BLUE Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
FDA restricts use of bluebird's gene therapy Skysona due to increased blood cancer risk - Endpoints News
Sickle Cell Disease Pipeline 2025: FDA Approvals, Therapies, Clinical Trials, And Latest Developments Unveiled By Delveinsight Sanofi, Novartis AG, Bluebird Biotech, Pfizer Inc., Aruvant Sciences - Menafn
Technical analysis overview for bluebird bio Inc. stockFree Entry Plan for Oversold Reversal Stocks - Newser
Cerebral Adrenoleukodystrophy Market: Leriglitazone, Gene Therapies Signal New Era Across 7MM | DelveInsight - Barchart.com
Gene Therapy Market Set to Witness Significant Growth - openPR.com
What's Going On With Bluebird Bio Stock? - 富途牛牛
What institutional flow reveals about bluebird bio Inc.Technical Safety Zone Pattern Recognition - Newser
Should I hold or sell bluebird bio Inc. stock in 2025Get timely alerts on top market movers - Jammu Links News
Is bluebird bio Inc. stock overvalued or undervaluedRemarkably fast returns - Jammu Links News
Is it the right time to buy bluebird bio Inc. stockMaximize your returns with portfolio optimization - Jammu Links News
Is bluebird bio Inc. a growth stock or a value stockDiscover stocks with superior performance - Jammu Links News
What makes bluebird bio Inc. stock price move sharplyUnlock exclusive trading strategies for gains - Jammu Links News
How strong is bluebird bio Inc. company’s balance sheetGet expert alerts on market-moving stocks - Jammu Links News
What catalysts could drive bluebird bio Inc. stock higher in 2025Rapidly expanding wealth - Jammu Links News
How does bluebird bio Inc. generate profit in a changing economyInvest confidently with data-driven strategies - Jammu Links News
How does bluebird bio Inc. compare to its industry peersUnmatched market gains - Jammu Links News
How volatile is bluebird bio Inc. stock compared to the marketFree Buy/Sell Signal Notifications - Jammu Links News
What institutional investors are buying bluebird bio Inc. stockInvest smarter with data-backed trading alerts - Jammu Links News
What are the technical indicators suggesting about bluebird bio Inc.Advanced Screener Ideas For Every Investor - Jammu Links News
How many analysts rate bluebird bio Inc. as a “Buy”Low Risk Alerts Backed By Experts - Jammu Links News
Why bluebird bio Inc. stock attracts strong analyst attentionCapital Preserving Trade Plan Templates Shared - beatles.ru
What are the latest earnings results for bluebird bio Inc.Outstanding capital appreciation - Jammu Links News
What drives bluebird bio Inc. stock priceOver 200% growth - PrintWeekIndia
What analysts say about bluebird bio Inc. stock outlookAccelerated earnings growth - jammulinksnews.com
Is bluebird bio Inc. a good long term investmentSuperior stock selection - PrintWeekIndia
Finanzdaten der Bluebird Bio Inc-Aktie (BLUE)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.94%
1.72%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):